CA3247162A1 - Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses - Google Patents

Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses

Info

Publication number
CA3247162A1
CA3247162A1 CA3247162A CA3247162A CA3247162A1 CA 3247162 A1 CA3247162 A1 CA 3247162A1 CA 3247162 A CA3247162 A CA 3247162A CA 3247162 A CA3247162 A CA 3247162A CA 3247162 A1 CA3247162 A1 CA 3247162A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
traps
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247162A
Other languages
English (en)
French (fr)
Inventor
Xin Cheng
Yingtao LIU
Luoheng Qin
Feng Ren
Huaxing Yu
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of CA3247162A1 publication Critical patent/CA3247162A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3247162A 2022-01-28 2023-01-28 Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses Pending CA3247162A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022074739 2022-01-28
CNPCT/CN2022/074739 2022-01-28
CN2022140318 2022-12-20
CNPCT/CN2022/140318 2022-12-20
PCT/CN2023/073579 WO2023143520A1 (en) 2022-01-28 2023-01-28 Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3247162A1 true CA3247162A1 (en) 2023-08-03

Family

ID=87470622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247162A Pending CA3247162A1 (en) 2022-01-28 2023-01-28 Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses

Country Status (12)

Country Link
US (1) US20250101019A1 (https=)
EP (1) EP4469456A4 (https=)
JP (1) JP2025502943A (https=)
KR (1) KR20240142481A (https=)
CN (1) CN118871439A (https=)
AR (1) AR128383A1 (https=)
AU (1) AU2023213905A1 (https=)
CA (1) CA3247162A1 (https=)
IL (1) IL313821A (https=)
MX (1) MX2024009216A (https=)
TW (1) TW202340190A (https=)
WO (1) WO2023143520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074128A1 (en) * 2022-10-08 2024-04-11 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
CN121793967A (zh) * 2023-07-06 2026-04-03 英矽智能科技知识产权有限公司 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025026377A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912874A1 (en) * 1990-08-15 1992-02-26 British Bio Technology Compounds
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP2099796B1 (en) * 2006-11-30 2011-06-01 Genentech, Inc. Aza-indolyl compounds and methods of use
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
CN111615388B (zh) * 2017-07-27 2023-11-14 斯汀格瑞治疗股份有限公司 癌症免疫治疗剂
CN111732584B (zh) * 2019-03-25 2024-02-27 复旦大学 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途
JP7598875B2 (ja) * 2019-04-12 2024-12-12 リボサイエンス リミティド ライアビリティ カンパニー エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体
CN115151253B (zh) * 2019-09-23 2025-04-15 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
CA3291973A1 (en) * 2021-01-29 2026-03-02 Txinno Bioscience Inc. Benzotriazole Derivative Having Inhibitory Activity Against Ectonucleotide Pyrophosphatase-Phosphodiesterase, and Use Thereof

Also Published As

Publication number Publication date
IL313821A (en) 2024-08-01
US20250101019A1 (en) 2025-03-27
EP4469456A4 (en) 2025-12-31
CN118871439A (zh) 2024-10-29
KR20240142481A (ko) 2024-09-30
AU2023213905A1 (en) 2024-07-11
MX2024009216A (es) 2024-08-06
WO2023143520A1 (en) 2023-08-03
AR128383A1 (es) 2024-04-24
EP4469456A1 (en) 2024-12-04
TW202340190A (zh) 2023-10-16
JP2025502943A (ja) 2025-01-30

Similar Documents

Publication Publication Date Title
CA3247162A1 (en) Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
Staats et al. Biofilm formation in periprosthetic joint infections
Xue et al. Artificial intelligence-assisted bioinformatics, microneedle, and diabetic wound healing: a “new deal” of an old drug
Lee et al. Codelivery of sustainable antimicrobial agents and platelet-derived growth factor via biodegradable nanofibers for repair of diabetic infectious wounds
US10517892B2 (en) Methods and systems for inhibiting foreign-body responses in diabetic patients
EP3570932A1 (en) Medication infusion components and systems
Thevenot et al. The pivotal role of fibrocytes and mast cells in mediating fibrotic reactions to biomaterials
Carmona et al. In vitro effects of platelet-rich gel supernatants on histology and chondrocyte apoptosis scores, hyaluronan release and gene expression of equine cartilage explants challenged with lipopolysaccharide
US20230270827A1 (en) Systems, Methods and Products for Minimizing Tissue Reactions and Tissue Injury at an Infusion Site
Güran et al. Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apopitotic factors
Xu et al. [Retracted] Platelet‐Rich Plasma‐Derived Exosomal USP15 Promotes Cutaneous Wound Healing via Deubiquitinating EIF4A1
Choi et al. Injectable PLGA microspheres encapsulating WKYMVM peptide for neovascularization
JP2018526460A (ja) 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法
Kesserwan et al. Advancing continuous subcutaneous insulin infusion in vivo: New insights into tissue challenges
Sheng et al. Advanced phosphocreatine-grafted chitosan hydrogel promote wound healing by macrophage modulation
Tang-Schomer et al. Film interface for drug testing for delivery to cells in culture and in the brain
Yang et al. Cell volume regulation modulates macrophage-related inflammatory responses via JAK/STAT signaling pathways
Wang et al. Decorated small intestinal submucosa (SIS) based bio-patch with anti-fouling and vascularized capacity to accelerate chronic wound regeneration via TGF-β and MAPK pathway
Gessmann et al. Peripheral blood plasma clot as a local antimicrobial drug delivery matrix
Chung et al. Chan
Jin et al. Microneedle Assisted Melittin‐Chondroitin Sulfate Administration for the Transdermal Therapy of Rheumatoid Arthritis
Duan et al. Light rare earth elements hinder bone development via inhibiting type H vessels formation in mice
Le et al. NanoPDLIM2-based combination therapy for lung cancer treatment in mouse preclinical studies
US20250090729A1 (en) Methods and Products to Detect, Minimize and Treat TRAP-Related Tissue Reactions and Tissue Injury Associated With Medical Devices
Keeler et al. Effects of delayed delivery of dexamethasone-21-phosphate via subcutaneous microdialysis implants on macrophage activation in rats

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240705

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241029

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241029

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124